Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -54.09% is 78% above its 4-year average of -247.18%, near the high end of its 4-year range (-720.88%–-40.96%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.27% below its 12-month average of -51.87%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -54.09%.
RETURN ON EQUITY (ROE)
-54.09%
RETURN ON EQUITY (ROE) AVG TTM
-51.87%
RETURN ON EQUITY (ROE) AVG 3Y
-187.59%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-4.27%
CURRENT VS 3Y AVG
+71.17%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-28.75%
vs the sector median at left
Aclarion, Inc.
Market Cap
$6.60M
Return on Equity (ROE)
-54.09%
TTM Avg
-51.87%
3Y Avg
-187.59%
5Y Avg
N/A
Market Cap
$6.60M
Return on Equity (ROE)
N/A
TTM Avg
-266.00%
3Y Avg
851.50%
5Y Avg
629.05%
Market Cap
$6.61M
Return on Equity (ROE)
-143.54%
TTM Avg
-132.34%
3Y Avg
-104.07%
5Y Avg
-91.90%
Market Cap
$6.58M
Return on Equity (ROE)
-108.00%
TTM Avg
-445.77%
3Y Avg
-254.63%
5Y Avg
-239.85%
Market Cap
$6.74M
Return on Equity (ROE)
-227.37%
TTM Avg
-118.13%
3Y Avg
-87.25%
5Y Avg
-55.09%
Market Cap
$6.88M
Return on Equity (ROE)
-847.90%
TTM Avg
-134.62%
3Y Avg
-211.14%
5Y Avg
-242.56%
Market Cap
$6.28M
Return on Equity (ROE)
-304.78%
TTM Avg
-566.96%
3Y Avg
-321.57%
5Y Avg
-251.82%
Market Cap
$7.04M
Return on Equity (ROE)
-111.46%
TTM Avg
-348.97%
3Y Avg
-374.13%
5Y Avg
-408.25%
Market Cap
$7.07M
Return on Equity (ROE)
-218.65%
TTM Avg
-54.74%
3Y Avg
-35.36%
5Y Avg
-35.36%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aclarion, Inc. (ACON) | $6.60M | -54.09% | -51.87% | -187.59% | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.60M | N/A | -266.00% | 851.50% | 629.05% |
| Biomerica, Inc. (BMRA)vs › | $6.61M | -143.54% | -132.34% | -104.07% | -91.90% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.58M | -108.00% | -445.77% | -254.63% | -239.85% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.74M | -227.37% | -118.13% | -87.25% | -55.09% |
| Exicure, Inc. (XCUR)vs › | $6.88M | -847.90% | -134.62% | -211.14% | -242.56% |
| Femasys Inc. (FEMY)vs › | $6.28M | -304.78% | -566.96% | -321.57% | -251.82% |
| KALA BIO, Inc. (KALA)vs › | $7.04M | -111.46% | -348.97% | -374.13% | -408.25% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | -218.65% | -54.74% | -35.36% | -35.36% |
| Scienture Holdings, Inc. (SCNX)vs › | $6.11M | -59.21% | -23.87% | -948.19% | -660.49% |
ROE
-54.1%
ROA
-51.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -54.09% |
| 2026-03-31 | -40.96% |
| 2025-12-31 | -56.36% |
| 2025-09-30 | -58.67% |
| 2025-06-30 | -49.29% |
| 2025-03-31 | -42.02% |
| 2024-12-31 | -720.88% |
| 2024-09-30 | -249.77% |
| 2024-06-30 | -359.31% |
| 2024-03-31 | -244.55% |
| 2023-03-31 | -684.45% |
| 2022-12-31 | -334.82% |
| 2022-09-30 | -315.76% |
| 2022-06-30 | -249.55% |
